ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
April 15, 2019 10:30 ET
|
Schall Law
LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc....
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Zogenix, Inc. (ZGNX) and Encourages ZGNX Investors to Contact the Firm
April 12, 2019 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 12, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California...
Bragar Eagel & Squire, P.C. is Investigating Zogenix, Inc. (ZGNX) on Behalf of Stockholders and Encourages ZGNX Investors to Contact the Firm
April 10, 2019 20:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against Zogenix, Inc. (NASDAQ: ZGNX). Our investigation concerns whether Zogenix has...
Zogenix Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
April 10, 2019 11:30 ET
|
Block & Leviton LLP
BOSTON, April 10, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Zogenix, Inc....
Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results
August 09, 2016 16:01 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Agreement to Refinance Debt, Further Increasing Company’s Expected 2017 Cash Balance
June 21, 2016 08:00 ET
|
Zogenix, Inc.
- Interest-only repayment provision results in $10 million increase to Zogenix’s expected cash balance at the end of 2017 - EMERYVILLE, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc....
Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
May 05, 2016 08:00 ET
|
Zogenix, Inc.
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine...
Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
January 19, 2016 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...